Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV

CONCLUSION: Less than half of our study population achieved anti-pneumococcal seroprotective levels following PCV13 and PPV23 immunization. Low pre-vaccination GMC levels were associated with non-response. Further research is required to optimize vaccination strategies that achieve higher seroprotection in this high-risk group.PMID:37316406 | DOI:10.1016/j.vaccine.2023.06.021

Source: Vaccine - June 14, 2023 Category: Allergy & Immunology Authors: Michaela Tinggaard Hans-Christian Slotved Charlotte Sv ærke Jørgensen Gitte Kronborg Thomas Benfield Source Type: research